IBOGF (Universal Ibogaine) Receivables Turnover: 1.77 (As of Apr. 2025)

What is Universal Ibogaine Receivables Turnover?

Universal Ibogaine IBOGF -1.07% Receivables Turnover is 1.77 as of Apr. 2025.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Universal Ibogaine's Revenue for the three months ended in Apr. 2025 was $0.50 Mil. Universal Ibogaine's average Accounts Receivable for the three months ended in Apr. 2025 was $0.28 Mil. Hence, Universal Ibogaine's Receivables Turnover for the three months ended in Apr. 2025 was 1.77.

Universal Ibogaine (OTCPK:IBOGF) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Universal Ibogaine Receivables Turnover Related Terms

Universal Ibogaine Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine Receivables Turnover Chart

Universal Ibogaine Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Jul22

Jul23

Jul24

Receivables Turnover

Get a 7-Day Free Trial

0.00

Universal Ibogaine Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25
Receivables Turnover	Get a 7-Day Free Trial															2.43	2.57	3.06	2.22	1.77

IBOGF vs LABT, CALC, LNAI: Receivables Turnover Comparison

For the Biotechnology subindustry, Universal Ibogaine's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine Receivables Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's Receivables Turnover falls into.

Save Embed

Universal Ibogaine Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Universal Ibogaine's Receivables Turnover for the fiscal year that ended in Jul. 2024 is calculated as

	Receivables Turnover (A: Jul. 2024 )
=	Revenue	/	Average Accounts Receivable
=	Revenue (A: Jul. 2024 )	/ (	(Accounts Receivable (A: Jul. 2023 )	+	Accounts Receivable (A: Jul. 2024 ))	/	count )
=	1.7	/ (	(0	+	0)	/	1 )
=	1.7	/	0
=	N/A

Universal Ibogaine's Receivables Turnover for the quarter that ended in Apr. 2025 is calculated as

	Receivables Turnover (Q: Apr. 2025 )
=	Revenue	/	Average Accounts Receivable
=	Revenue (Q: Apr. 2025 )	/ (	(Accounts Receivable (Q: Jan. 2025 )	+	Accounts Receivable (Q: Apr. 2025 ))	/	count )
=	0.501	/ (	(0.131	+	0.435)	/	2 )
=	0.501	/	0.283
=	1.77

Frequently Asked Questions Learn more about Receivables Turnover →

What does a Receivables Turnover of 1.77 mean?

Universal Ibogaine (IBOGF) has a Receivables Turnover of 1.77 as of Apr. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Universal Ibogaine and its competitors.

Is Universal Ibogaine's Receivables Turnover too high?

Universal Ibogaine's current Receivables Turnover is 1.77. The Biotechnology industry median Receivables Turnover is 5.30. Universal Ibogaine's value of 1.77 is 66.6% below this industry median.

How does Universal Ibogaine's Receivables Turnover compare to LABT and CALC?

Universal Ibogaine's Receivables Turnover of 1.77 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.30. Universal Ibogaine's value of 1.77 is 66.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Receivables Turnover for a Biotechnology company?

The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universal Ibogaine's current Receivables Turnover of 1.77 is 66.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Receivables Turnover mean?

A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Universal Ibogaine and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universal Ibogaine's current Receivables Turnover is 1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Universal Ibogaine stock overvalued right now?

Universal Ibogaine (IBOGF) has a current Receivables Turnover of 1.77. The current Receivables Turnover is 1.77 and 66.6% below the Biotechnology industry median of 5.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Receivables Turnover calculated?

Receivables Turnover is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current Receivables Turnover is 1.77 as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Industry Healthcare Biotechnology

Comparable Companies LABT CALC LNAI BCDA PBM BOLT IMNN CURX BIVI PMCB VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL ONC RVMD XKRX:068270

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2

Website https://www.universalibogaine.com

Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.